Dr. Reddy's Laboratories Ltd. (RDY)’s Announces The Launch Of Sumatriptan Injection USP, Autoinjector System
2/26/2014 8:36:47 AM
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (NYSE: RDY) announced yesterday that it has launched Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 mL For Subcutaneous Use, a therapeutic equivalent generic version of IMITREX STATdose Pen® (sumatriptan succinate) 6 mg/0.5 mL in the US market on February 25, 2014, following the approval by the United States Food & Drug Administration (USFDA).
Help employers find you! Check out all the jobs and post your resume.
comments powered by